Alopecia

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.

Recent research shows the long-term benefits and safety of low-level laser therapy for androgenetic alopecia.

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.

Discover how vitamin D receptor signaling influences hair follicle health and alopecia, revealing new therapeutic possibilities for hair loss management.

Legacy Healthcare has advanced Cinainu into a phase 3 study for alopecia areata, offering hope for effective, safe treatment without immunosuppression.

Spizuoco leads the inaugural DermVIP Summit, enhancing alopecia education for dermatology professionals through expert insights and innovative treatments.

Experts discuss real-world strategies for managing alopecia areata, emphasizing JAK inhibitors, psychosocial impacts, and personalized patient care approaches.

GT20029 shows promising results in treating androgenetic alopecia, enhancing hair density with minimal adverse effects in men after 12 weeks.

Cosmo Pharmaceuticals reveals promising phase 3 results for clascoterone 5% solution, showing significant hair growth improvement in alopecia.

Arash Mostaghimi, MD, MPH, FAAD, and experts discuss evolving treatment standards for alopecia areata, focusing on JAK inhibitors, patient-centered care, and future therapeutic innovations.

Discover how a proprietary extract from saw palmetto promotes hair growth and reduces thinning in adults, offering a safe alternative to traditional treatments.

New research reveals ritlecitinib's potential to reverse scarring alopecias by targeting inflammation, offering hope for hair regrowth in autoimmune disorders.

Veradermics initiates a groundbreaking trial for VDPHL01, an oral minoxidil treatment, addressing female pattern hair loss with innovative solutions.

Experts discuss hair loss challenges and treatments for skin of color, highlighting the importance of early intervention and accurate diagnosis.

At Elevate-Derm Fall, Victoria Garcia-Albea, NP, details the expanding educational landscape in hair disease management, the rise of dedicated hair health meetings, and practical pathways for clinicians looking to advance professionally through writing.

Victoria Garcia-Albea, NP, outlined evolving therapeutic strategies at Elevate-Derm Fall, highlighting low-dose oral minoxidil, off-label JAK inhibition for frontal fibrosing alopecia, Thiamidol in hyperpigmentation, and delgocitinib for chronic hand eczema.

At 52 weeks, the data presented at Fall Clinical showed that 64.8% and 63.3% of adolescents on baricitinib 4 mg achieved significant eyebrow and eyelash regrowth, respectively.

The trial evaluates ritlecitinib's efficacy for severe alopecia areata, utilizing innovative external placebo controls for enhanced patient outcomes.

A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.

The investigational extended-release tablet maintained therapeutic plasma levels while avoiding peaks linked to cardiovascular risk.

Upadacitinib shows promising results in treating severe alopecia areata, achieving significant hair regrowth and setting new efficacy standards in therapy.

Jerry Shapiro, MD, shares innovative strategies for diagnosing and managing scarring alopecia at Maui Derm NP+PA Fall 2025, enhancing patient outcomes.

Alopecia areata treatment advances with targeted therapies, improving patient outcomes and access while addressing the emotional impact of hair loss.

Vimal Prajapati, MD, FRCPC, DABD, highlighted key findings from the THRIVE-AA trials, noting the efficacy of deuruxolitinib 8 mg BID, its favorable safety profile, and its positioning alongside other JAK inhibitors.

Happy Head's StrandIQ system revolutionizes hair loss treatment with personalized genetic analysis, enhancing hair growth and scalp health for individuals.